$APLS
Apellis Pharmaceuticals, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023035935 Filed on July 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $110.4M $94.97M
YoY Change 400.54% 481.85%
Cost Of Revenue $22.40M $8.379M
YoY Change 1522.01% 10118.29%
Gross Profit $88.00M $86.59M
YoY Change 325.63% 433.19%
Gross Profit Margin 79.71% 91.18%
Selling, General & Admin $145.6M $111.4M
YoY Change 85.7% 8.83%
% of Gross Profit 165.45% 128.62%
Research & Development $79.42M $95.66M
YoY Change -16.58% -5.9%
% of Gross Profit 90.25% 110.47%
Depreciation & Amortization $460.0K $425.0K
YoY Change 14.71% 10.1%
% of Gross Profit 0.52% 0.49%
Operating Expenses $247.5M $207.0M
YoY Change 41.42% 25.51%
Operating Profit -$137.1M -$120.4M
YoY Change -10.37% -18.96%
Interest Expense -$2.300M -$1.339M
YoY Change -54.85% -80.92%
% of Operating Profit
Other Income/Expense, Net -$603.0K -$63.00K
YoY Change -709.09% -142.28%
Pretax Income -$140.0M -$121.8M
YoY Change -26.63% -21.64%
Income Tax $200.0K $194.0K
% Of Pretax Income
Net Earnings -$140.2M -$122.0M
YoY Change -26.68% -21.76%
Net Earnings / Revenue -127.03% -128.5%
Basic Earnings Per Share -$1.17 -$1.02
Diluted Earnings Per Share -$1.17 -$1.02
COMMON SHARES
Basic Shares Outstanding 117.7M 116.5M
Diluted Shares Outstanding 120.3K 119.3K

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $452.4M $616.3M
YoY Change -36.15% -27.74%
Cash & Equivalents $452.4M $616.3M
Short-Term Investments
Other Short-Term Assets $30.85M $44.91M
YoY Change 28.93% 57.81%
Inventory $98.55M $103.2M
Prepaid Expenses $44.62M $34.40M
Receivables $169.3M $110.9M
Other Receivables $17.70M $17.39M
Total Short-Term Assets $796.8M $892.7M
YoY Change -4.23% -7.01%
LONG-TERM ASSETS
Property, Plant & Equipment $4.790M $22.07M
YoY Change -15.68% 274.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.175M $827.0K
YoY Change -92.54% -94.79%
Total Long-Term Assets $21.45M $22.89M
YoY Change -47.63% -46.17%
TOTAL ASSETS
Total Short-Term Assets $796.8M $892.7M
Total Long-Term Assets $21.45M $22.89M
Total Assets $818.2M $915.6M
YoY Change -6.26% -8.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.19M $27.50M
YoY Change 29.03% 69.54%
Accrued Expenses $117.1M $103.6M
YoY Change 46.77% 15.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $44.60M $43.77M
YoY Change 176.23% 176.28%
Total Short-Term Liabilities $185.6M $174.8M
YoY Change 60.79% 37.89%
LONG-TERM LIABILITIES
Long-Term Debt $388.5M $382.8M
YoY Change -10.24% -26.8%
Other Long-Term Liabilities $946.0K $12.50M
YoY Change -51.19% 696.37%
Total Long-Term Liabilities $946.0K $395.3M
YoY Change -51.19% 25096.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $185.6M $174.8M
Total Long-Term Liabilities $946.0K $395.3M
Total Liabilities $585.9M $570.2M
YoY Change 3.62% -14.65%
SHAREHOLDERS EQUITY
Retained Earnings -$2.700B -$2.600B
YoY Change 26.0% 33.22%
Common Stock $12.00K $12.00K
YoY Change 9.09% 9.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $232.3M $345.4M
YoY Change
Total Liabilities & Shareholders Equity $818.2M $915.6M
YoY Change -6.26% -8.67%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$140.2M -$122.0M
YoY Change -26.68% -21.76%
Depreciation, Depletion And Amortization $460.0K $425.0K
YoY Change 14.71% 10.1%
Cash From Operating Activities -$169.1M -$150.2M
YoY Change 9.5% 40.3%
INVESTING ACTIVITIES
Capital Expenditures $50.00K $372.0K
YoY Change -125.51% -195.14%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$50.00K -$372.0K
YoY Change -100.04% -100.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.740M 1.560M
YoY Change -40.43% -132.95%
NET CHANGE
Cash From Operating Activities -169.1M -150.2M
Cash From Investing Activities -50.00K -372.0K
Cash From Financing Activities 5.740M 1.560M
Net Change In Cash -163.4M -149.0M
YoY Change 717.07% 416.71%
FREE CASH FLOW
Cash From Operating Activities -$169.1M -$150.2M
Capital Expenditures $50.00K $372.0K
Free Cash Flow -$169.1M -$150.5M
YoY Change 9.67% 41.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001492422
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38276
dei Entity Registrant Name
EntityRegistrantName
APELLIS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-1537290
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Fifth Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
977-5700
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
APLS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
117737289
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
616259000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
551801000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
110913000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7727000
CY2023Q2 us-gaap Inventory Net
InventoryNet
103216000
CY2022Q4 us-gaap Inventory Net
InventoryNet
85714000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
34404000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
36350000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
1085000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1273000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
26809000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
36658000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
892686000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
719523000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16726000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18747000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5339000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6148000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
827000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15799000
CY2023Q2 us-gaap Assets
Assets
915578000
CY2022Q4 us-gaap Assets
Assets
760217000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
27500000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
37342000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
97716000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
95139000
CY2023Q2 apls Development Liability Current
DevelopmentLiabilityCurrent
43769000
CY2022Q4 apls Development Liability Current
DevelopmentLiabilityCurrent
29504000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5852000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5625000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
174837000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
167610000
CY2023Q2 apls Development Liability Noncurrent
DevelopmentLiabilityNoncurrent
289960000
CY2022Q4 apls Development Liability Noncurrent
DevelopmentLiabilityNoncurrent
315647000
CY2023Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
92883000
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
92736000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12066000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14352000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
429000
CY2023Q2 us-gaap Liabilities
Liabilities
570175000
CY2022Q4 us-gaap Liabilities
Liabilities
590345000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
117579000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
117579000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110772000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
110772000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
12000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2954862000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2479596000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-796000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-875000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2608675000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2308860000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
345403000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
169872000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
915578000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
760217000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94969000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16322000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
139814000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30703000
CY2023Q2 apls Operating Cost Of Sales
OperatingCostOfSales
8379000
CY2022Q2 apls Operating Cost Of Sales
OperatingCostOfSales
82000
apls Operating Cost Of Sales
OperatingCostOfSales
16188000
apls Operating Cost Of Sales
OperatingCostOfSales
1329000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95658000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101661000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
205684000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
192606000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
111373000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
63203000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
213466000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
114390000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
215410000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
164946000
us-gaap Operating Expenses
OperatingExpenses
435338000
us-gaap Operating Expenses
OperatingExpenses
308325000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-120441000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-148624000
us-gaap Operating Income Loss
OperatingIncomeLoss
-295524000
us-gaap Operating Income Loss
OperatingIncomeLoss
-277622000
CY2023Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
6002000
CY2022Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1432000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
11395000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1530000
CY2023Q2 apls Interest Expense Nonoperating
InterestExpenseNonoperating
7341000
CY2022Q2 apls Interest Expense Nonoperating
InterestExpenseNonoperating
8448000
apls Interest Expense Nonoperating
InterestExpenseNonoperating
14869000
apls Interest Expense Nonoperating
InterestExpenseNonoperating
16986000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
149000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-341000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-140000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-121843000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-155491000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-299339000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-293218000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
194000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
486000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
476000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1694000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-122037000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-155977000
us-gaap Net Income Loss
NetIncomeLoss
-299815000
us-gaap Net Income Loss
NetIncomeLoss
-294912000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-766000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-818000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-21000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-369000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
79000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-286000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-21000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1135000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
79000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1104000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-122058000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-157112000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-299736000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-296016000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
119316
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
119316
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106630
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106630
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116594
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116594
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102349
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102349
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
169872000
CY2023Q1 apls Issuance Of Common Stock And Pre Funded Warrants In Common Stock Offering
IssuanceOfCommonStockAndPreFundedWarrantsInCommonStockOffering
384387000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17718000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-10999000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28823000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-177778000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
100000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
412123000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22334000
CY2023Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-27000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29277000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3754000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-122037000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-21000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
345403000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
198662000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
380120000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2416000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20773000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-52000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-138935000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
83000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
462235000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4770000
CY2022Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-536000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22530000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2531000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-766000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-155977000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-369000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-334418000
us-gaap Profit Loss
ProfitLoss
-299815000
us-gaap Profit Loss
ProfitLoss
-294912000
us-gaap Share Based Compensation
ShareBasedCompensation
58101000
us-gaap Share Based Compensation
ShareBasedCompensation
43303000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-19000
apls Operating Lease Right Of Use Asset And Right Of Use Liability Amortization Expense Reversal
OperatingLeaseRightOfUseAssetAndRightOfUseLiabilityAmortizationExpenseReversal
-37000
apls Operating Lease Right Of Use Asset And Right Of Use Liability Amortization Expense Reversal
OperatingLeaseRightOfUseAssetAndRightOfUseLiabilityAmortizationExpenseReversal
-61000
us-gaap Depreciation
Depreciation
846000
us-gaap Depreciation
Depreciation
763000
apls Amortization Of Discounts For Convertible Notes Net Of Financing Costs
AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts
147000
apls Amortization Of Discounts For Convertible Notes Net Of Financing Costs
AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts
290000
apls Accretion Of Discount To Development Liability
AccretionOfDiscountToDevelopmentLiability
13078000
apls Accretion Of Discount To Development Liability
AccretionOfDiscountToDevelopmentLiability
13336000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1571000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
103186000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2584000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
17502000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
32134000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2535000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3390000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-9846000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-42225000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-14977000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-15757000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9849000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2591000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3065000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-17287000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-327775000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-218584000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
631000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
477000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
331863000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
143320000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-631000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-189020000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
384387000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
380120000
apls Payments For Development Liability
PaymentsForDevelopmentLiability
24500000
apls Payments For Development Liability
PaymentsForDevelopmentLiability
16500000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40052000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8770000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3754000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2531000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
11027000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2952000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
392666000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
371969000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-365000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
64269000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36000000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
553075000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
641755000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
617344000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
605755000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
616259000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
604489000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
1085000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
1266000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
617344000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
605755000
us-gaap Interest Paid Net
InterestPaidNet
1643000
us-gaap Interest Paid Net
InterestPaidNet
3360000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
384000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
156000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of Organization and Operations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Apellis Pharmaceuticals, Inc. (the “Company”) is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was incorporated in September 2009 under the laws of the State of Delaware. The Company’s principal executive offices are located in Waltham, Massachusetts.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital, developing its product candidates, commercializing EMPAVELI (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (“PNH”) and the commercializing of SYFOVRE (pegcetacoplan injection) for the treatment of geographic atrophy secondary to age-related macular degeneration (“GA”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the realization of assets and t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he satisfaction of liabilities and commitments in the normal course of business. From inception to June 30, 2023, the Company has incurred cash outflows from operations, losses from operations and had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion primarily as a result of expenses incurred through a combination of research and development activities related to our various product candidates and expenses supporting those activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of July 31, 2023, the date of issuance of these unaudited condensed consolidated financial statements, the Company believes that its cash and cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">616.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of June 30, 2023 combined with its cash flows generated from sales will be sufficient to fund its operations and capital expenditures for at least the next twelve months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s future viability beyond that point is dependent on its ability to achieve commercial success for SYFOVRE and EMPAVELI. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are uncertainties associated with the Company’s ability to (1) obtain additional debt or equity financing on terms that are favorable to the Company, (2) enter into collaborative agreements with strategic partners, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations or is not able to obtain funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts and its business could be materially harmed.</span></p>
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2600000000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
616300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: development liability, accrued expenses, prepaid expenses, convertible debt and taxes.</span></p>
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
110900000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7700000
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
32711000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
29847000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
48368000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
54101000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
22137000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1766000
CY2023Q2 us-gaap Inventory Net
InventoryNet
103216000
CY2022Q4 us-gaap Inventory Net
InventoryNet
85714000
CY2023Q2 apls Down Payments For Inventory Current
DownPaymentsForInventoryCurrent
3644000
CY2022Q4 apls Down Payments For Inventory Current
DownPaymentsForInventoryCurrent
13987000
CY2023Q2 apls Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
18964000
CY2022Q4 apls Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
15181000
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
11796000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7182000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
34404000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
36350000
CY2023Q2 apls Royalties Receivable Current
RoyaltiesReceivableCurrent
2386000
CY2022Q4 apls Royalties Receivable Current
RoyaltiesReceivableCurrent
1442000
CY2022Q4 apls Employee Retention Credit Current
EmployeeRetentionCreditCurrent
8711000
CY2023Q2 apls Receivable From Collaboration Agreement Current
ReceivableFromCollaborationAgreementCurrent
15000000
CY2022Q4 apls Receivable From Collaboration Agreement Current
ReceivableFromCollaborationAgreementCurrent
20000000
CY2023Q2 apls Deposits And Other Current Assets
DepositsAndOtherCurrentAssets
9423000
CY2022Q4 apls Deposits And Other Current Assets
DepositsAndOtherCurrentAssets
6505000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
26809000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
36658000
CY2022Q2 apls Contractual Interest Expense
ContractualInterestExpense
1680000
apls Contractual Interest Expense
ContractualInterestExpense
1643000
apls Contractual Interest Expense
ContractualInterestExpense
3360000
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
896000
CY2023Q2 apls Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
31240000
CY2022Q4 apls Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
34849000
CY2023Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3357000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
907000
CY2023Q2 apls Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
39744000
CY2022Q4 apls Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
43212000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
23375000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16171000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
97716000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
95139000
CY2023Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
74000
CY2022Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
145000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
147000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
290000
CY2023Q2 apls Contractual Interest Expense
ContractualInterestExpense
822000
us-gaap Operating Lease Cost
OperatingLeaseCost
2900000
us-gaap Operating Lease Payments
OperatingLeasePayments
4094000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
1825000
us-gaap Interest Expense Debt
InterestExpenseDebt
1790000
us-gaap Interest Expense Debt
InterestExpenseDebt
3650000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1644000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
3286000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3286000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
96225000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
104441000
CY2023Q2 us-gaap Longterm Debt Percentage Bearing Fixed Interest Amount
LongtermDebtPercentageBearingFixedInterestAmount
10544000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1014000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
92883000
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company enters into lease agreements with terms generally ranging from 2-7 years. Some of the Company’s lease agreements include Company options to extend the lease on a month-to-month basis or for set periods for up to five years. Many of these leases also include options to terminate the leases within one year or per other contractual terms. Renewal and termination options were generally not included in the lease term for the Company’s existing operating leases.
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
apls Lessee Operating Lease Maximum Term Of Options To Terminate Lease
LesseeOperatingLeaseMaximumTermOfOptionsToTerminateLease
P1Y
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16726000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18747000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
17918000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
19977000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M13D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M25D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0721
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0726
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1700000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1500000
us-gaap Operating Lease Cost
OperatingLeaseCost
3400000
us-gaap Operating Lease Payments
OperatingLeasePayments
3532000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3528000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6416000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5253000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4339000
CY2023Q2 apls Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
556000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
20092000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2174000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
17918000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
500000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
apls Minimum Percentage Of Tax Position Likelihood Of Being Realized Upon Examination By Taxing Authorities
MinimumPercentageOfTaxPositionLikelihoodOfBeingRealizedUponExaminationByTaxingAuthorities
0.50
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17713000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21191000

Files In Submission

Name View Source Status
0000950170-23-035935-index-headers.html Edgar Link pending
0000950170-23-035935-index.html Edgar Link pending
0000950170-23-035935.txt Edgar Link pending
0000950170-23-035935-xbrl.zip Edgar Link pending
apls-20230630.htm Edgar Link pending
apls-20230630.xsd Edgar Link pending
apls-ex31_1.htm Edgar Link pending
apls-ex31_2.htm Edgar Link pending
apls-ex32_1.htm Edgar Link pending
apls-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
apls-20230630_def.xml Edgar Link unprocessable
apls-20230630_pre.xml Edgar Link unprocessable
apls-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apls-20230630_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
apls-20230630_cal.xml Edgar Link unprocessable